Arrowhead Pharmaceuticals $ARWR
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-34
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO29%
Delay Index: of 7 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Arrowhead Pharmaceuticals on the live radar map → 📅 $ARWR readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ARO-ALK7 NCT06937203 |
P1/2 | Recruiting | Obesity; Diabetes Mellitus, Type 2 | 150 | 2027-02 (-7 mo) |
| ARO-MAPT-SC NCT07221344 |
P1/2 | Recruiting | Alzheimer Disease; Tauopathies | 160 | 2027-06 |
| ARO-DIMERPA NCT07223658 |
P1/2 | Recruiting | Hyperlipidemia; Mixed | 78 | 2027-07 |
| zodasiran Injection NCT07037771 |
P3 | Active, not recruiting | Homozygous Familial Hypercholesterolemia | 70 | 2027-08-20 |
| ARO-INHBE NCT06700538 |
P1/2 | Active, not recruiting | Obesity | 190 | 2027-10-15 (+21 mo) |
| ARO-RAGE NCT07241546 |
P2 | Recruiting | Asthma | 36 | 2027-12 |
| SHASTA-10 NCT06822790 |
P3 | Active, not recruiting | Hypertriglyceridemia | 710 | 2028-07 |
| SPRUCE NCT07473843 |
P3 | Recruiting | Homozygous Familial Hypercholesterolemia | 10 | 2028-07 |
| SHASTA-5 NCT06880770 |
P3 | Recruiting | Severe Hypertriglyceridemia | 288 | 2029-03 (+12 mo) |
| ARO-INHBE NCT07859813 |
P2 | Not yet recruiting | Metabolic Dysfunction-Associated Steatohepatitis | 252 | 2029-10 |